DOCSLIB.ORG

Prior Authorization List for Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prior Authorization List for Drugs Medical Prior Authorization List (For Drugs Administered in an Office, Home or Outpatient Setting) Effective August 1, 2021 THIS LIST APPLIES TO ALL COMMERCIAL FULLY-INSURED MEMBERS Certain drugs require prior authorization in order to be covered under your health plan. Prior authorization review is the process of determining the medical necessity of a proposed procedure, surgery or treatment (including prescribed drug intervention) relative to approved criteria. Prior authorization is required to ensure that the drug is medically necessary and you will receive the benefits to which you are entitled. Requests for prior authorization must be received before the services or drugs are provided/ administered. Failure of a network provider to contact SummaCare for required authorization of items covered under your benefit plan will relieve the health plan and you from any financial responsibility for the service if those services are rendered before notifying the plan. Certain drugs that require prior authorization may also be subject to SummaCare’s Site of Care Policy. These drugs are noted with “++”. For more information refer to the policy on our website at: https://www.summacare.com/providers/provider-policies/pharmacy-policies NOTE: Your in-network providers are responsible for obtaining authorization 48 hours prior to administering these prescription drugs. If you use a provider that is not in your network, it is your responsibility to obtain any required prior authorization. For Providers: Network providers are responsible for obtaining authorization at least 48 hours before rendering these prescription drugs. How to request prior authorization for drugs covered under the medical benefit: • Fax submission of requests for prior authorization should be used for non-urgent requests. • Routine requests: Fax 234-231-7082 • Urgent requests: Call 330-996-8710 or 888-996-8710 (TTY 800-750-0750) • Oncology requests: For all drugs marked with “*” Call 855-774-1315 SummaCare provides coverage under the medical benefit for many drugs that are administered in an office, home or outpatient setting. We require certain drugs to receive prior authorization before being administered. The following drugs may require prior authorization: 5FU (fluorouracil) * ADRIAMYCIN (doxorubicin) * ABILIFY MAINTENA (aripiprazole) ADVATE (factor product) ABRAXANE (paclitaxel) * ADYNOVATE (factor product) ACTEMRA (tocilizumab) * ++ AFSTYLA (factor product) ACTHAR GEL (corticotropin) AKYNZEO (fosnetupitant/palonosetron) * ACTIMMUNE (interferon gamma-1b) * ALDURAZYME (laronidase) ++ ADAGEN (pegademase) ALIMTA (premetrexed disodium) * ADAKVEO (crizanlizumab-tmca) ALIQOPA (copsnlidib) * ADCETRIS (brentuximab vedotin) * ALKERAN (melphalan) * 1 Medical Prior Authorization List (For Drugs Administered in an Office, Home or Outpatient Setting) ALOXI (palonosetron) * CEREZYME (imiglucerase) ++ ALPHANATE (antihemophilic factor) CERUBIDINE (daunorubicin) * ALPHANINE SD (antihemophilic factor) CIMZIA (certolizumab pegol) ++ ALPROLIX (factor product) CINRYZE (C1 inhibitor) ++ AMONDYS (casimersen) CINQAIR (reslizumab) ANDEXXA (andexanet alfa) CINVANTI (aprepitant) * ARA-C (cytarabine) * CLOLAR (clofarabine) * ARALAST (alpha proteinase inhibitor) ++ COAGADEX (factor product) ARANESP (darbepoetin alfa) * CORIFACT (factor product) ARCALYST (rilonacept) COSELA (trilaciclib) * AREDIA (pamidronate disodium) * COSMEGEN (dactinomycin) * ARISTADA/ARISTADA INITIO (aripiprazole lauroxil) CRYSVITA (burosumab-twza) * ARRANON (nelarabine) * CUVITRU (immune globulin) ARZERRA (ofatumumab) * CYRAMZA (ramucirumab) * ASCENIV (immune globulin) ++ CYTOGAM (cytomegalovirus immune globulin) ++ ASPARLAS (calaspargase pegol-mknl) * CYTOXAN (cyclophosphamide) * ATGAM (antithymocyte globulin) ++ DACOGEN (decitabine)* AVASTIN (bevacizumab) * DANYELZA (naxitamab-gqgk) * AVONEX (interferon beta-1a) DARZALEX (daratumumab) * AVSOLA (infliximab-axxq)++ DARZALEX FASPRO (daratumumab-hyaluronidase) * AZEDRA (iobenguane I 131) DEPOCYT (cytarabine-liposome) * BAVENCIO (avelumab) * DOJOLVI (triheptanoin) BCNU (carmustine)* DOXIL (doxorubicin-liposome) * BEBULIN/BEBULIN VH (factor product) DTIC-DOME (dacarbazine) * BELEODAQ (belinostat) * DUROLANE (hyaluronate and derivatives) BELRAPZO (bendamustine hcl)* DYSPORT (abobotulinumtoxin A) BENDEKA (bendamustine hcl) * ELAPRASE (idursulfase) ++ BENEFIX (factor product) ELELYSO (taliglucerase–alfa) BENLYSTA IV (belimumab) ELIGARD (leuprolide acetate)* BERINERT (c1 esterase inhibitor) ++ ELLENCE (epirubicin) * BESPONSA (inotuzumab ozogamicin) * ELOCTATE (factor product) BIVIGAM (immune globulin) ++ ELOXATIN (oxaliplatin) * BLENOXANE (bleomycin) * ELZONRIS (tagraxofusp-erzs) * BLENREP (belantamab mafodotin-blmf) * EMPLICITI (elotuzumab) * BLINCYTO (blinatumomab) * EMPAVELI (pegcetacoplan) BONIVA IV (ibandronate) ENHERTU (fam-trastuzumab deruxtecan-nxki) * BOTOX (onabotulinumtoxin A) ENTYVIO (vedolizumab) ++ BRINEURA (cerliponase) EPOGEN (epoetin alfa) * CABENUVA (cabotegravir/rilpivirine) ERBITUX (cetuximab) * CABLIVI (caplacizumab-yhdp) ERWINAZE (asparaginase) * CAMPTOSAR (irinotecan) * ESPEROCT (factor product) CARIMUNE (immune globulin) EVENITY (romosozumab-aqqg) CAYSTON (aztreonam) inhalation EVKEEZA (evinacumab-dgnb) 2 Medical Prior Authorization List (For Drugs Administered in an Office, Home or Outpatient Setting) EVOMELA (melphalan)* IDAMYCIN (idarubicin) * EXONDYS 51 (eteplirsen) IDELVION (factor product) EXCLUDED FROM COVERAGE IFEX (ifosfamide) * FABRAZYME (agalsidase) ++ ILARIS (canakinumab) FASENRA (benralizumab) ILUMYA (tildrakizumab-asmn) FASLODEX (fluvestrant) * IMFINZI (durvalumab) * FEIBA NF (factor product) IMLYGIC (talimogene laherparepvec) * FENSOLVI (leuprolide acetate) * INFLECTRA (infliximab-dyyb) ++ FIRMAGON (degarelix) * INFUGEM (gemcitabine) * FLEBOGAMMA (immune globulin) ++ INTRON A (interferon alfa-2b) * FLOLAN (epoprostenol) INVEGA SUSTENNA (paliperidone palmitate ER) FLUDARA (fludarabine) * INVEGA TRINZA (paliperidone palmitate) FOLOTYN (pralatrexate) * ISTODAX (romidepsin)* FUDR (floxuridine) * IXEMPRA (ixabepilone) * FULPHILA (pegfilgrastim-jmbd) * IXINITY (factor product) FUSILEV (levoleucovorin) * JELMYTO (mitomycin)* GAMASTAN (immune globulin) ++ JEMPERLI (dostarlimab-gxly) * GAMIFANT (emapalumab-lzsg) JEVTANA (cabazitaxel) * GAMMAGARD (immune globulin) ++ JIVI (factor product) GAMMAKED (immune globulin) ++ KADCYLA (trastuzumab emtansine) * GAMMAPLEX (immune globulin) ++ KANJINTI (trastuzumab-anns) * GAMUNEX-C (immune globulin) ++ KANUMA (sebelipase) ++ GAZYVA (obinutuzumab) * KCENTRA (factor product) GEL-ONE (hyaluronate and derivatives) KEYTRUDA (pembrolizumab) * GELSYN (hyaluronate and derivatives) KHAPZORY (levoleucovorin) * GENVISC (hyaluronate and derivatives) KOATE (factor product) GEMZAR (gemcitabine) * KOGENATE FS (factor product) GIVLAARI (givosiran) KOVALTRY (factor product) GLASSIA (proteinase inhibitor) ++ KRYSTEXXA (pegloticase) GRANIX (tbo-filgrastim) * KYMRIAH (tisagenleceucel) HALAVEN (eribulin mesylate) * KYPROLIS (carfilzomib) * HELIXATE FS (factor product) LARTRUVO (olaratumab)* HEMLIBRA (emicizumab-kxwh) LEMTRADA (alemtuzumab) HEMOFIL M (antihemophilic factor) LEUCOVORIN * HERCEPTIN (trastuzumab) * LEUKINE (sargramostim) * HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) * LEUSTATIN (cladribine) * HERZUMA (trastuzumab-pkrb) * LIBTAYO (cemiplimab-rwic) * HIZENTRA (immune globulin) LUMIZYME (alglucosidase) ++ HUMATE-P (factor product) LUMOXITI (moxetumomab psaudotox-tdfk) * HYALGAN (hyaluronate and derivatives) LUPRON DEPOT (leuprolide acetate) * HYCAMTIN (topotecan) * LUTATHERA (lutetium lu177 dotatate) HYMOVIS (hyaluronate and derivatives) LUXTURNA (voretigene neparvovec-rzyl) HYQVIA (immune globulin) MARGENZA (margetuximab) 3 Medical Prior Authorization List (For Drugs Administered in an Office, Home or Outpatient Setting) MARQIBO (vincristine sulfate liposome) * PADCEV (enfortumab vedotin-piiq) * MEPSEVII (vestronidase alfa-vjbk) PANZYGA (immune globulin-ifas) ++ MESNEX (mesna) * PARAPLATIN (carboplatin) * METHOTREXATE * PARSABIV (etelcalcetide) MIRCERA (methoxy polyethylene glycol-epoetin beta) PEGASYS (peginterferon alfa-2a) * MONJUVI (tafasitamb-cxix) * PEGINTRON (peginterferon alfa-2b) * MONOCLATE-P (factor product) PEPAXTO (melphalan flufenamide) * MONONINE (factor product) PERJETA (pertuzumab) * MONOVISC (hyaluronate and derivatives) PERSERIS (risperidone) PHESGO (pertuzumab, trastuzumab, and MOZOBIL (plerixafor) hyaluronidase) * MUSTRAGEN (mechlorethamine) * PHOTOFRIN (porfimer) * MUTAMYCIN (mitomycin) * PLATINOL (cisplatin) * MVASI (bevacizumab-awwb) * POLIVY (polatuzumab vedotin-piiq) * MYLOTARG (gemtuzumab ozogamicin) * PORTRAZZA (necitumumab) * MYOBLOC (rimabotulinumtoxin B) POTELIGEO (mogamulizumab-kpkc) * NAGLAZYME (galsulfase) PRIVIGEN (immune globulin) ++ NAVELBINE (vinorelbine) * PROBUPHINE IMPLANT (buprenorphine) NEULASTA (pegfilgrastim) * PROCRIT (epoetin alfa) * NEUPOGEN (filgrastim) * PROFILNINE SD (factor product) NIPENT (pentostatin) * PROLASTIN (alpha proteinase inhibitor) ++ NIVESTYM (filgrastim-aafi) * PROLEUKIN (aldesleukin) * NOVANTRONE (mitoxantrone) * PROLIA (denosumab) NOVOEIGHT (factor product) PROVENGE (sipuleucel-T) * NOVOSEVEN RT (factor product) QUTENZA (capsaicin 8% patch) NPLATE (romiplostim) QUZYTTIR (cetirizine hcl) NUCLALA (mepolizumab) RADICAVA (edaravone) ++ NULOJIX (belatacept) REBINYN (factor product) NUWIQ (factor product) REBLOZYL (luspatercept-aamt) * NYVEPRIA (pegfilgrastim-apgf) * RECLAST (zoledronic acid) OBIZUR (antihemophilic factor) RECOMBINATE (factor
Load more

Recommended publications
  • SPECIALTY MEDICATIONS Available Through Accredo Health Group, Inc., Medco’S Specialty Pharmacy Call Toll-Free (800) 803-2523, 8:00 A.M
    SPECIALTY MEDICATIONS available through Accredo Health Group, Inc., Medco’s specialty pharmacy Call toll-free (800) 803-2523, 8:00 a.m. to 8:00 p.m., eastern time, Monday through Friday, to confirm that your medication is covered. Effective as of July 1, 2011 Abraxane® (paclitaxel protein-bound particles) Berinert® (C 1 esterase inhibitor [human])* (PA) (QD) Actemra ™ (tocilizumab) (PA) Betaseron® (interferon beta-1b) (PA) Actimmune® (interferon gamma-1b) (PA) Botox® (botulinum toxin type A) (PA) Adagen® (pegademase bovine) Carbaglu ™ (carglumic acid) Adcirca® (tadalafil) (ST) (QD) Carimune® NF (immune globulin intravenous [human]) (PA) Advate® (antihemophilic factor [recombinant]) (CPA) Cerezyme® (imiglucerase) (CPA) (ST) Afinitor® (everolimus) (PA) (QD) Cimzia® (certolizumab pegol) (ST) Aldurazyme® (laronidase) (CPA) Copaxone® (glatiramer acetate) (PA) Alphanate® (antihemophilic factor [human]) (CPA) Copegus® (ribavirin) (ST) AlphaNine® SD (coagulation factor IX [human]) (CPA) Corifact® (factor XIII [human]) (CPA) Amevive® (alefacept) (PA) Cystadane® (betaine) Ampyra ™ (dalfampridine) (PA) CytoGam® (cytomegalovirus immune globulin Apokyn® (apomorphine hydrochloride) (PA) (QD) intravenous [human])* (CPA) Aralast® (alpha[1]-proteinase inhibitor [human]) Cytovene® IV (ganciclovir sodium)* Aranesp® (darbepoetin alfa) (PA) Dacogen® (decitabine) Arcalyst® (rilonacept) (PA) (QD) Dysport® (abobotulinumtoxinA) (PA) Arixtra® (fondaparinux sodium)* Egrifta ™ (tesamorelin) (PA) Arranon® (nelarabine) Elaprase® (idursulfase) (CPA) Arzerra® (ofatumumab)
    [Show full text]
  • Antibody–Drug Conjugates
    Published OnlineFirst April 12, 2019; DOI: 10.1158/1078-0432.CCR-19-0272 Review Clinical Cancer Research Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index Steven Coats1, Marna Williams1, Benjamin Kebble1, Rakesh Dixit1, Leo Tseng1, Nai-Shun Yao1, David A. Tice1, and Jean-Charles Soria1,2 Abstract Since the first approval of gemtuzumab ozogamicin nism of activity of the cytotoxic warhead. However, the (Mylotarg; Pfizer; CD33 targeted), two additional antibody– enthusiasm to develop ADCs has not been dampened; drug conjugates (ADC), brentuximab vedotin (Adcetris; Seat- approximately 80 ADCs are in clinical development in tle Genetics, Inc.; CD30 targeted) and inotuzumab ozogami- nearly 600 clinical trials, and 2 to 3 novel ADCs are likely cin (Besponsa; Pfizer; CD22 targeted), have been approved for to be approved within the next few years. While the hematologic cancers and 1 ADC, trastuzumab emtansine promise of a more targeted chemotherapy with less tox- (Kadcyla; Genentech; HER2 targeted), has been approved to icity has not yet been realized with ADCs, improvements treat breast cancer. Despite a clear clinical benefit being dem- in technology combined with a wealth of clinical data are onstrated for all 4 approved ADCs, the toxicity profiles are helping to shape the future development of ADCs. In this comparable with those of standard-of-care chemotherapeu- review, we discuss the clinical and translational strategies tics, with dose-limiting toxicities associated with the mecha- associated with improving the therapeutic index for ADCs. Introduction in antibody, linker, and warhead technologies in significant depth (2, 3, 8, 9). Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving Overview of ADCs in Clinical Development the therapeutic index (the ratio between the toxic dose and the Four ADCs have been approved over the last 20 years (Fig.
    [Show full text]
  • Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
    Published OnlineFirst April 20, 2017; DOI: 10.1158/0008-5472.CAN-16-2523 Cancer Perspective Research Whither Radioimmunotherapy: To Be or Not To Be? Damian J. Green1,2 and Oliver W. Press1,2,3 Abstract Therapy of cancer with radiolabeled monoclonal antibodies employing multistep "pretargeting" methods, particularly those has produced impressive results in preclinical experiments and in utilizing bispecific antibodies, have greatly enhanced the thera- clinical trials conducted in radiosensitive malignancies, particu- peutic efficacy of radioimmunotherapy and diminished its toxi- larly B-cell lymphomas. Two "first-generation," directly radiola- cities. The dramatically improved therapeutic index of bispecific beled anti-CD20 antibodies, 131iodine-tositumomab and 90yttri- antibody pretargeting appears to be sufficiently compelling to um-ibritumomab tiuxetan, were FDA-approved more than a justify human clinical trials and reinvigorate enthusiasm for decade ago but have been little utilized because of a variety of radioimmunotherapy in the treatment of malignancies, particu- medical, financial, and logistic obstacles. Newer technologies larly lymphomas. Cancer Res; 77(9); 1–6. Ó2017 AACR. "To be, or not to be, that is the question: Whether 'tis nobler in the pembrolizumab (anti-PD-1), which are not directly cytotoxic mind to suffer the slings and arrows of outrageous fortune, or to take for cancer cells but "release the brakes" on the immune system, arms against a sea of troubles, And by opposing end them." Hamlet. allowing cytotoxic T cells to be more effective at recognizing –William Shakespeare. and killing cancer cells. Outstanding results have already been demonstrated with checkpoint inhibiting antibodies even in far Introduction advanced refractory solid tumors including melanoma, lung cancer, Hodgkin lymphoma and are under study for a multi- Impact of monoclonal antibodies on the field of clinical tude of other malignancies (4–6).
    [Show full text]
  • Monoclonal Antibodies
    MONOCLONAL ANTIBODIES ALEMTUZUMAB ® (CAMPATH 1H ) I. MECHANISM OF ACTION Antibody-dependent lysis of leukemic cells following cell surface binding. Alemtuzumab is a recombinant DNA-derived humanized monoclonal antibody that is directed against surface glycoprotein CD52. CD52 is expressed on the surface of normal and malignant B and T lymphocytes, NK cells, monocytes, macrophages, a subpopulation of granulocytes, and tissues of the male reproductive system (CD 52 is not expressed on erythrocytes or hematopoietic stem cells). The alemtuzumab antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine monoclonal antibody (campath 1G). II. PHARMACOKINETICS Cmax and AUC show dose proportionality over increasing dose ranges. The overall average half-life is 12 days. Peak and trough levels of Campath rise during the first weeks of Campath therapy, and approach steady state by week 6. The rise in serum Campath concentration corresponds with the reduction in malignant lymphocytes. III. DOSAGE AND ADMINISTRATION Campath can be administered intravenously or subcutaneously. Intravenous: Alemtuzumab therapy should be initiated at a dose of 3 mg administered as a 2-hour IV infusion daily. When the 3 mg dose is tolerated (i.e., ≤ Grade 2 infusion related side effects), the daily dose should be escalated to 10mg and continued until tolerated (i.e., ≤ Grade 2 infusion related side effects). When the 10 mg dose is tolerated, the maintenance dose of 30 mg may be initiated. The maintenance dose of alemtuzumab is 30 mg/day administered three times a week on alternate days (i.e. Monday, Wednesday, and Friday), for up to 12 weeks.
    [Show full text]
  • F. Gherlinzoni CD33: Gemtuzumab Ozogamicin
    1ST CUNEO CITY IMMUNOTHERAPY CONFERENCE 17-18 Maggio 2018 PASSIVE IMMUNOTHERAPY ANTIBODY-DRUG CONJUGATES GEMTUZUMAB OZOGAMICIN Do#. Filippo Gherlinzoni Direore Unità Operava Complessa di Ematologia Ospedale “Ca’ Foncello” - Treviso IL RIECCOLO Blood Reviews 28 (2014) 143–153 Contents lists available at ScienceDirect Blood Reviews journal homepage: www.elsevier.com/locate/blre REVIEW The past and future of CD33 as therapeutic target in acute myeloid leukemia a a,b a,b,c, George144 S. Laszlo , Elihu H. Estey , Roland B. Walter ⁎G.S. Laszlo et al. / Blood Reviews 28 (2014) 143–153 a Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA b Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA c Department of Epidemiology, University of Washington, Seattle, WA, USA as cytokine-induced cellular proliferation [14,33]. Engagement with CD33 antibodies has similarly been shown to affect cytokine and article info abstract chemokine secretion by monocytes, although both increases [34] or Keywords: CD33 is a myeloid differentiation antigen with endocytic properties.decreases It is broadly[33] expressedhave on been acute myeloidobserved in vitro. Acute myeloid leukemia leukemia (AML) blasts and, possibly, some leukemic stem cells and has therefore been exploited as target for Antibody therapeutic antibodies for many years. The improved survival seen in many patients when the antibody-drug Antibody-drug conjugate conjugate, gemtuzumab ozogamicin, is added to conventional chemotherapy validates this approach. However, fi 2.3. Endocytic properties of CD33 Bispeci c antibody many attempts with unconjugated or conjugated antibodies have been unsuccessful, highlighting the challenges BiTE of targeting CD33 in AML.
    [Show full text]
  • Antibody–Drug Conjugates: the Last Decade
    pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
    [Show full text]
  • Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
    CCR FOCUS Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin Alejandro D. Ricart Abstract Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently sensitive to cytotoxic agents. CD33 and CD22 are specific markers of myeloid leukemias and B-cell malignancies, respectively. These endocytic receptors are ideal for an ADC strategy because they can effectively carry the cytotoxic payload into the cell. Gemtuzumab ozogamicin (GO, Mylotarg) and inotuzumab ozogamicin consist of a derivative of calichea- micin (a potent DNA-binding cytotoxic antibiotic) linked to a humanized monoclonal IgG4 antibody directed against CD33 or CD22, respectively. Both of these ADCs have a target-mediated pharmacokinetic disposition. GO was the first drug to prove the ADC concept in the clinic, specifically in phase II studies that included substantial proportions of older patients with relapsed acute myeloid leukemia. In contrast, in phase III studies, it has thus far failed to show clinical benefit in first-line treatment in combination with standard chemotherapy. Inotuzumab ozogamicin has shown remarkable clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma, and it has started phase III evaluation. The safety profile of these ADCs includes reversible myelosuppression (especially neutropenia and thrombocyto- penia), elevated hepatic transaminases, and hyperbilirubinemia. There have been postmarketing reports of hepatotoxicity, especially veno-occlusive disease, associated with GO. The incidence is 2%, but patients who undergo hematopoietic stem cell transplantation have an increased risk. As we steadily move toward the goal of personalized medicine, these kinds of agents will provide a unique opportunity to treat selected patient subpopulations based on the expression of their specific tumor targets.
    [Show full text]
  • What Lessons Can We Learn from 20 Years of Chemokine T D Di ? Receptor
    What lessons can we learn from 20 years of chemokine receptdtor drug discovery? John G. Cumming, PhD 5th RSC / SCI symposium on GPCRs in Medicinal Chemistry 15th-17th September 2014, Actelion, Allschwil, Basel, Switzerland Outline Background: chemokines and their receptors Chemokine receptor drug discovery and development Emerging opportunities for chemokine drug discovery Conclusions and learning Chemokines and chemokine receptors CXC(α) • Chemokines (chemoattractant cytokines) are 70-120 aa proteins • 44 chemokines in 4 major families and 22 chemokine receptors in human genome • ‘Cell positioning system’ in the body • Many receptors bind multiple ligands • Many ligands bind multiple receptors Chemotaxis Human monocytes + CCL2 (red) Volpe et al. PLoS ONE 2012, 7(5), e37208 CCR2 antagonists inhibit chemotaxis and infiltration Vasculature CCL2 release Spinal or Peripheral Tissue Recruited monocyte Site of CCL2 release CCR2 antagonists inhibit chemotaxis and infiltration CCR2 antagonist Circulating monocyte CCL2 release CCL2 release from peripheral injury site or central PAF terminals Role of chemokine system in pathophysiology • Potential role in inflammatory and autoimmune diseases: Multiple sclerosis, Rheumatoid arthritis, COPD, allergic asthma, IBD, psoriasis - Expression levels of chemokines and receptors in relevant tissues and organs of patients and animal disease models - Mouse knockout ppyphenotype in disease models • Established role in HIV infection Katschke et al., 2001 Arthritis Rheum, 44, 1022 - CCR5 and CXCR4 act as HIV-1
    [Show full text]
  • Systemic Therapy Update
    Systemic Therapy Update Volume 24 Issue 2 February 2021 For Health Professionals Who Care for Cancer Patients Inside This Issue: Editor’s Choice Revised Protocols, PPPOs and Patient Handouts COVID-19 Vaccine Guidance | New Programs: Ribociclib BR: BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, BRAJACTW, BRAJCAP, and Fulvestrant for Advanced Breast Cancer BRAJLHRHAI, BRAJLHRHT, BRAJTTW, BRAVCAP, BRAVCLOD, BRAVEVEX, (UBRAVRBFLV) | Bevacizumab, Cisplatin and Paclitaxel for BRAVGEMT, BRAVLCAP, BRAVLHRHA, BRAVLHRHT, UBRAVPALAI, BRAVPTRAT, Gynecologic Malignancies (GOCISPBEV) | Gemtuzumab UBRAVRIBAI, BRAVTAX, BRAVTCAP, BRAVTW, BRLACTWAC, BRLATACG, BRLATWAC | GI: GIAAVCT, GIAJCAP, GIAJCAPOX, GIAJFFOX, GIAJRALOX, Ozogamicin with Chemotherapy for AML (ULKGEMOZ) | GIAVCAP, GIAVCAPB, GIAVCRT, GIAVTZCAP, GICAPIRI, GICAPOX, GICART, Bortezomib, Lenalidomide and Dexamethasone for GICIRB, GICOXB, GICPART, GIEFFOXRT, GIENACTRT, GIFFIRB, GIFFOXB, Untreated Multiple Myeloma (UMYBLDF) | Paclitaxel for UGIFFOXPAN, GIFIRINOX, GIFOLFOX, GIGAJCOX, GIGAJCPRT, GIGAJFFOX, Metastatic Angiosarcoma (SAAVTW) | Cemiplimab for GIGAVCC, GIGAVCCT, GIGAVCFT, GIGAVCOX, GIGAVCOXT, GIGAVFFOX, Cutaneous Squamous Cell Carcinoma (USMAVCEM) GIGAVFFOXT, GIGAVRAMT, GIGECC, GIGFLODOC, UGINETEV, GIPAJFIROX, GIPAJGCAP, GIPAVCAP, GIPNEVER, GIRAJCOX, GIRAJFFOX, GIRCAP, GIRCRT, Drug Update GIRINFRT | GO: GOCABR, GOCABRBEV, GOCISP, GOCXAJCAT, GOCXCAT, IV Famotidine to Replace IV Ranitidine GOCXCATB, GOCXCRT, GOENDCAT, GOOVBEVLD, GOOVBEVP, GOOVCATB, Medication Safety Corner GOOVCATM, GOOVCATR,
    [Show full text]
  • Supplementary Material Table of Contents
    Supplementary M aterial Table of Contents 1 - Online S u pplementary Methods ………………………………………………...… . …2 1.1 Study population……………………………………………………………..2 1.2 Quality control and principal component analysis …………………………..2 1.3 Statistical analyses………………………………………… ………………...3 1.3.1 Disease - specific association testing ……………………………… ..3 1.3.2 Cross - phenotype meta - analysis …………………………………… .3 1.3.3 Model search ……………………………………………………… .4 1.3.4 Novelty of the variants …………………………………………… ..4 1.3.5 Functional Enrichment Analy sis ………………………………… ...4 1.3.6 Drug Target Enrichment Analysis ………………………………… 5 2 - Supplementary Figures………………………………………...………………… . …. 7 3 - Members of the Myositis Genetics Consortium (MYOGEN) ……………………. ..16 4 - Members of the Scleroderma Genetics Consortium ………………… ……………...17 5 - Supplementary References………………………………………………………… . .18 6 - Supplementary Tables………………………………………………………… . ……22 1 Online supplementary m ethods Study population This study was conducted using 12,132 affected subjects and 23 ,260 controls of European des cent population and all of them have been included in previously published GWAS as summarized in Table S1. [1 - 6] Briefly, a total of 3,255 SLE cases and 9,562 ancestry matched controls were included from six countrie s across Europe and North America (Spain, Germany, Netherlands, Italy, UK, and USA). All of the included patients were diagnosed based on the standard American College of Rheumatology (ACR) classification criteria. [7] Previously described GWAS data from 2,363 SSc cases and 5,181 ancestry
    [Show full text]
  • Mozobil (Plerixafor Injection) AHM
    Mozobil (Plerixafor Injection) AHM Clinical Indications • Mozobil (Plerixafor Injection) in combination with granulocyte-colony stimulating factor (G-CSF) is considered medically necessary to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation for patients who have failed a prior mobilization attempts with G-CSF with 1 or more of the following conditions o Lymphoma (i.e., Hodgkin's disease and non-Hodgkin's lymphoma) o Multiple myeloma o Germ cell tumors o WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome • Current role remains uncertain. Based on review of existing evidence, there are currently no clinical indications for this technology. See Inappropriate Uses for more detailed analysis of the evidence base. Mozobil is considered investigational for all other indications Evidence Summary • Background • There has been a steady rise in the use of peripheral blood stem cells (PBSC) as a source of hematopoietic stem cells. In general, less than 0.05 % of white blood cells (WBC) are CD34+ cells. Chemotherapy results in a 5- to 15-fold increase of PBSC. Chemotherapy in combination with growth factors increases CD34+ cells up to 6 % of WBC. In the allogeneic setting, granulocyte-colony stimulating factor (G-CSF) is used alone for mobilization of PBSC. Several factors affect PBSC mobilization; including age, gender, type of growth factor, dose of the growth factor, and in the autologous setting, the patient's diagnosis, chemotherapy regimen and number of previous chemotherapy cycles or radiation. Muscle and bone pain are common side effects in allogeneic stem cell mobilization, but are usually tolerated with the use of analgesics.
    [Show full text]
  • The Role of Monoclonal Antibodies in the Management of Leukemia
    Pharmaceuticals 2010, 3, 3258-3274; doi:10.3390/ph3103258 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Role of Monoclonal Antibodies in the Management of Leukemia Ali Al-Ameri 1, Mohamad Cherry 2, Aref Al-Kali 1 and Alessandra Ferrajoli 1,* 1 Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX 77005, USA 2 Department of Internal Medicine, Hematology Oncology section, Oklahoma University Health Sciences Center, 700 N.E. 13th Street, Oklahoma City, OK 74103, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-713-792-2063. Received: 20 September 2010 / Accepted: 18 October 2010 / Published: 18 October 2010 Abstract: This article will review the monoclonal antibodies more commonly used in leukemias. In the last three decades, scientists have made considerable progress understanding the structure and the functions of various surface antigens, such as CD20, CD33. The introduction of rituximab, an anti CD20 monoclonal antibody, had a great impact in the treatment of lymphoproliferative disorders. Gemtuzumab, an anti CD 33 conjugated monoclonal antibody has activity in acute mylegenous leukemia (AML). As this field is undergoing a rapid growth, the years will see an increasing use of monoclonal antibodies in hematological malignancies. Keywords: monoclonal Abs; leukemia; CLL; AML; ALL 1. Introduction In 1900, speaking of monoclonal antibodies (MAbs), Paul Ehrlich proposed that “immunizations such as these which are of great theoretic interest may come to be available for clinical application attacking epithelium new formations, particularly carcinoma by means of specific anti-epithelial sera”[1]. Erlich’s dream came true with the first report of the manufacturing of MAb in 1975 by Kohler and Milstein [2,3].
    [Show full text]